1. The combination of an opioid receptor agonist and at least one anti-cancer agent used in the treatment of cancer, wherein (a) said opioid receptor agonist is administered to the patient in one or more than one dose until a therapeutically effective plasma level over a period of at at least one week, and (b) at least one anticancer agent selected from the group consisting of chemotherapeutic agents, cytotoxic agents, cytostatic agents, immunotoxic agents and / or for oterapii administered until a period with a therapeutically effective level in the plasma, and (c) the periods a) and b) perekryvayutsya.2. Combination according to Claim. 1, wherein said anticancer agent and said opioid receptor agonist are administered simultaneously or posledovatelno.3. Combination according to Claim. 1 wherein the opioid receptor agonist is able to inhibit cell proliferation and / or induce cell gibel.4. Combination according to Claim. 1, where the patient has received a preliminary treatment comprising an anticancer sredstvo.5. Combination according to Claim. 1, where the period of administration of the opioid receptor agonist that provides a therapeutically relevant dose is at least two weeks, preferably four weeks, and even more preferably a prolonged lechenie.6. . The combination of claim 1 wherein the opioid receptor agonist is selected from: 1) compounds of the methadone group, such as a D / L-methadone, D-methadone, L-methadone, normetadon, 2) derivatives of fentanyl, such as fentanyl, sufentanil, and carfentanil 3) morfinanovyh compounds such as morphine, codeine, heroin, dekstrallorfan, dextromethorphan, dekstrofanol, dimemorfan,1. Комбинация агониста опиоидного рецептора и по меньшей мере одного противоракового средства, применяемая в лечении рака, где:(а) указанный агонист опиоидного рецептора вводят пациенту в одной или более чем одной дозе до установления терапевтически эффективного уровня в плазме в течение периода, составляющего по меньшей мере одну неделю, и(б) по
